Report
Sanofi to pay Regeneron up to $8 billion to expand Dupixent partnership
Reuters reports Sanofi said it would pay $1 billion upfront and up to $7 billion in milestone payments to add four new antibodies.
TLDR
Reuters reports Sanofi said it would pay Regeneron $1 billion upfront and up to $7 billion in milestone payments to bring four new antibodies under their partnership behind the eczema drug Dupixent. Sanofi shares were 2% higher in early trading.
Combined views
67.4K
2 Sources, first seen 6h ago
23 likes6 comments6 saves6 reposts